Scalper1 News
Biogen’s (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech’s quarterly revenue growth to come in well below consensus estimates. The company also cut its full-year revenue guidance. Shares are plunging in giant volume in the stock market today, gapping down 18% to their lowest level in nearly eight months. The stock is now trading more than 30% off of Scalper1 News
Scalper1 News